<DOC>
	<DOCNO>NCT03059069</DOCNO>
	<brief_summary>The aim study investigate effect Gliatamin ( chonline alphoscerate ) depressive mood type 2 diabetes patient demonstrate impact improve depressive mood could influence patient 's quality life glycemic control .</brief_summary>
	<brief_title>The Effect Gliatamin ( Chonline Alphoscerate ) Depressive Mood Type 2 Diabetes Patients</brief_title>
	<detailed_description>The prevalence depressive disorder high individual chronic disease , screen management depression emphasize . Diabetes mellitus ( DM ) class chronic disease incidence DM increase . According previous study , 31.1 % patient DM accompany depressive disorder higher subject without DM . Furthermore , DM well depression know risk factor dementia . The choline metabolism involve neuropathology depressive disorder individual depressive disorder show low level choline concentration . Choline alphoscerate cholinergic precursor show favorable clinical result dementia management . As pseudodementia present depressive disorder choline alphoscerate would option case . Therefore , aim study investigate effect Gliatamin ( chonline alphoscerate ) depressive mood type 2 diabetes patient demonstrate impact improve depressive mood could influence patient 's quality life glycemic control .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetic patient Age ≥ 50 Glycemic control : HbA1c ≤ 10.0 % 10 ≤ Beck Depression Inventory ( BDI ) &lt; 30 point Participants undergo contraception case childbearing period Understands study procedure , alternative , risk voluntarily agree participate give write informed concent Type 1 diabetes , Secondary diabetes , gestational diabetes Ongoing dementia treatment antidepressive disorder medication Uncontrolled psychiatric disorder BDI ≥ 30 point Heavy alcoholic Underlying chronic liver disease ( hemochromatosis , liver cell carcinoma , autoimmune liver disease , liver cirrhosis , chronic viral hepatitis ) Allergy hypersensitivity target medication component Renal failure , moderate severe renal impairment ( estimate glomerular filtration rate &lt; 30 mL/min/1.73 m2 ) , ongoing dialysis Abnormal liver function ( AST/ALT &gt; x3 upper normal limit ) History alcohol drug abuse previous 3 month Premenopausal woman nurse pregnant Human immunodeficiency virus ( HIV ) human immunodeficiency virus ( AIDS ) chronic pancreatitis pancreatic cancer</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>